000 03498nam a22003735i 4500
001 81659
003 ES-MaUEC
005 20230207040340.0
007 cr nn 008mamaa
008 151103s2015 ne | s |||| 0|eng d
020 _a9789401772150
024 7 _a10.1007/978-94-017-7215-0
_2doi
050 4 _aRC267
_b.A383 2015
245 1 0 _aAdvances in Cancer Biomarkers :
_bFrom biochemistry to clinic for a critical revision
_cedited by Roberto Scatena.
250 _a1st ed. 2015.
260 _aDordrecht, Netherlands
_bSpringer
_c2015
300 _a1 recurso en línea (IX, 372 páginas)
_b27 ilustraciones, 21 ilustraciones en color
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
490 0 _aAdvances in Experimental Medicine and Biology
_x0065-2598
_v867
505 0 _aPrelims -- IÂ{u796E}nerality.-Â{u9260} Tumor markers-a critical revision -- Enzymes.-Â{u8BF2}rmones -- Oncofetal proteins.-Â{u3E74}tokeratins -- Carbohydrate markers -- Blood group antigens.-Â{u796E}netic markers -- Various protein markers -- IIIÂ{u0972}spectives.-Â{u4A25} role of Circulating tumor Cells as tumor markers -- Index.
520 3 _aAt present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes.Â{u026E}triguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simplyÂ{u0B6F}nitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirelyÂ{u0AEE}ow their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “pollutedâ€{u0AEE}owledge may have dramatic consequences for patient.The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
710 2 _aSpringerLink (Online service)
_0Local
_9106996
942 _2lcc
_cLE
988 _aEBOOK, asignarmaterias, EBSPRINGER,
650 2 7 _aFarmacología
_2embne
_9137893
650 7 _aFarmacología
_2embne
_9137893
700 1 _aScatena, Roberto
_eeditor literario
_994214
_0Local
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-94-017-7215-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907 _a.b12902494
_b10-10-17
_c18-01-16
998 _am
_a_alco
_a_vill
_b - -
_cm
_dz
_e-
_feng
_gne
_h0
945 _aRC267 .A383 2015 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i11572115
_z06-04-17
999 _c81659
_d81659
_x1